200 related articles for article (PubMed ID: 7741071)
1. [Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol].
Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Higashi Y; Negishi T
Hinyokika Kiyo; 1995 Mar; 41(3):191-6. PubMed ID: 7741071
[TBL] [Abstract][Full Text] [Related]
2. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
[TBL] [Abstract][Full Text] [Related]
3. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
J Med Invest; 1999 Feb; 46(1-2):55-8. PubMed ID: 10408158
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
Mahler C; Denis L
Am J Clin Oncol; 1988; 11 Suppl 2():S127-8. PubMed ID: 2977268
[TBL] [Abstract][Full Text] [Related]
6. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
[TBL] [Abstract][Full Text] [Related]
7. Severe flare-up in a prostate cancer patient treated with luteinizing hormone-releasing hormone analogue depot.
Shimizu T; Shibata Y; Uchida T; Satoh J
Hinyokika Kiyo; 1993 Oct; 39(10):953-5. PubMed ID: 8266863
[TBL] [Abstract][Full Text] [Related]
8. [Dynamic study of the hormonal levels and tumor markers after the first administration of long-acting LH-RH analogue in patients with prostate cancer].
Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Uchijima Y; Saitoh H
Hinyokika Kiyo; 1994 May; 40(5):393-400. PubMed ID: 7517620
[TBL] [Abstract][Full Text] [Related]
9. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
[TBL] [Abstract][Full Text] [Related]
10. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
[TBL] [Abstract][Full Text] [Related]
11. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
12. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
[TBL] [Abstract][Full Text] [Related]
13. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
[TBL] [Abstract][Full Text] [Related]
14. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
Shimada M; Uchida H; Kasahara T; Fuji K; Ogawa Y; Yoshida H; Hamajima T; Matsuda N; Ikeuchi T; Kai Y; Hiramori M; Hoshino M; Inoue K; Higaki Y
Hinyokika Kiyo; 1998 Jul; 44(7):525-32. PubMed ID: 9752613
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1.
Burzynski SR; Kubove E; Burzynski B
Drugs Exp Clin Res; 1990; 16(7):361-9. PubMed ID: 2152694
[TBL] [Abstract][Full Text] [Related]
17. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
Hinotsu S; Akaza H; Usami M; Ogawa O; Kagawa S; Kitamura T; Tsukamoto T; Naito S; Namiki M; Hirao Y; Murai M; Yamanaka H;
Jpn J Clin Oncol; 2007 Oct; 37(10):775-81. PubMed ID: 17965423
[TBL] [Abstract][Full Text] [Related]
18. Management of metastatic prostatic cancer.
Paulson DF
Urology; 1985 Feb; 25(2 Suppl):49-52. PubMed ID: 3918376
[TBL] [Abstract][Full Text] [Related]
19. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
[TBL] [Abstract][Full Text] [Related]
20. Reversibility of androgen deprivation therapy in patients with prostate cancer.
Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]